Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing novel biologic therapeutic candidates using proprietary modular protein engineering platforms and single-domain antibody (sdAb) technology. The company focuses on oncology, specifically targeting validated targets such as death-receptor 5 (DR5) and OX40 to induce cancer-specific programmed cell death. Its current clinical pipeline includes ozekibart (INBRX-109), a tetravalent DR5 agonist being investigated for chondrosarcoma, Ewing sarcoma, and colorectal cancer, and INBRX-106, a hexavalent OX40 agonist under investigation for non-small cell lung cancer and head and neck squamous cell carcinoma. Inhibrx Biosciences was formed in May 2024 as a spin-off from Inhibrx, Inc., following the sale of the INBRX-101 program to Sanofi. The company leverages its protein engineering expertise to optimize the valency of its therapeutics for target-centric agonist function.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage inhibrx.com
Sector Healthcare IR page inhibrx.com/inhibrx-biosciences-inc-investors
Tags
oncology, biologics, protein engineering, single-domain antibodies, sarcoma, colorectal cancer, lung cancer, head and neck cancer, clinical-stage, apoptosis, ozekibart, INBRX-109, INBRX-106, INBRX-101, INBRX-105, Sanofi, Inhibrx Inc.
Press page —

Metrics

Valuation  
Market cap $ 1.251B
Market cap (USD) $ 1.251B
P/E -9.38
PEG —
P/BV -14.57
P/S 962.52
P/OCF -9.64
P/FCF -9.64
Dividend yield —
Turnover / mcap —
Returns  
ROE -197.8%
ROI -129.0%
ROIC -93.3%
Profit margin -10,773.5%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 20
Quality score -73.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 1.3M 200K 1.8M 2.192M 7.231M 12.888M 13.211M
Net profit -140.055M 1.688B -241.361M -145.226M -81.768M -76.124M -51.4M
Free cash flow -129.825M -197.006M -197.902M -115.987M -81.187M -49.332M -33.889M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 82.96 15.4 38 24.64 43.67 32.97 —
Price performance 12m — — 0.54 -0.44 0.32 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 199,000 82,000 373,000 243,000 171,000 — —
↳ YoY growth -58.8% +354.9% -34.9% -29.6%
Borrowings, current (USD) — 3.56M 0.00 — — 0.00 — —
Borrowings, non-current (USD) — — — — — 207M 0.00 101M
Lease liabilities (USD) — 7.8M 8.21M 6.71M 5.03M 3.17M 8.05M 6.45M
Cash and deposits (USD) 2.1M 11.5M 129M 131M 274M 278M 153M 124M
Right-of-use assets (USD) — 7.45M 7.83M 6.34M 4.72M 2.95M 7.34M 5.54M
Net debt (borrowings + leases - cash) (USD) — -174,000 -120M — — -67.8M -145M -17.2M
Cash flow detail
Operating cash flow (USD) — -32.1M -48M -80.3M -115M -193M -194M -130M
Purchases of property, plant and equipment (USD) — -1.81M -1.36M -864,000 -686,000 -4.59M -2.6M -31,000
Change in receivables (cash effect) (USD) — 491,000 117,000 -167,000 130,000 -535,000 381,000 200,000
Change in payables (cash effect) (USD) — -3.47M 10.4M -4.64M -705,000 2.11M 17.9M -3.3M
Interest paid (cash effect) (USD) — -476,000 -504,000 -3.89M -13.1M -26.7M -11.5M -8.9M
Income taxes paid (cash effect) (USD) — -976,000 -3,000 -2,000 -4,000 -3,000 -2,000 -2,000
Share-based compensation (USD) — 3.97M 5.02M 15M 20.5M 24.8M 58.5M 11.1M
Operating cash flow before change in receivables (USD) — -32.6M -48.1M -80.2M -115M -193M -195M -130M
Free cash flow (OCF - PPE - intangibles) (USD) — -33.9M -49.3M -81.2M -116M -198M -197M -130M
Income detail
Research and development expense (USD) — 47.9M 73.5M 71.4M 110M 192M 204M 113M
↳ 5y CAGR +33.6% +9.0%
Reported Nov 13, 2020 Mar 12, 2021 Mar 12, 2021 Feb 28, 2022 Mar 6, 2023 May 9, 2024 Mar 17, 2025 Mar 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

- Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;

- 86.3% DCR, with durable responses observed in heavily pretreated patients

SAN DIEGO, CA - November 17, 2026/PRNewswire — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced updated clinical data from the Phase 1/2 expansion study evaluating ozekibart (INBRX-109), an investigational tetravalent death receptor 5 (DR5) agonist, in combination with irinotecan and temozolomide (IRI/TMZ) in patients with relapsed or refractory Ewing sarcoma. The data will be presented at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting.

“The updated clinical data to be presented at CTOS underscore the deep activity and expanding reach of ozekibart in aggressive, difficult-to-treat bone and soft tissue sarcomas,” said Mark Lappe, Chief Executive Officer of Inhibrx.

Inhibrx Reports Third Quarter 2026 Financial Results Bull 0 Bear 1 Results

San Diego, CA, November 13, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (Inhibrx or the Company) today reported financial results for the third quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials.

Upcoming Clinical Milestones

•Ozekibart (INBRX-109) in Ewing sarcoma. The Company plans to present updated results from the Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with irinotecan and temozolomide in refractory Ewing sarcoma at the annual Connective Tissue Oncology Society (CTOS) meeting in Seoul, South Korea from November 19th-20th, 2026.

•Ozekibart (INBRX-109) in Chondrosarcoma. Commercial readiness activities advancing in line with the regulatory review timeline for ozekibart (INBRX-109) in chondrosarcoma.

•Ordastobart (INBRX-106) in HNSCC. The Company is currently enrolling the Phase 2 portion of the randomized HexAgon study in head and neck squamous cell carcinoma (HNSCC) in combination with pembrolizumab, which is expected to add approximately 50 additional HPV-positive Oropharyngeal Squamous Cell Carcinoma patients to support a potential accelerated regulatory pathway.

On September 28, 2026, Inhibrx Biosciences, Inc. (the “Company”) posted an updated copy of its corporate presentation to the “Investors” tab of its website at www.inhibrx.com. The presentation is attached to this Current Report on Form 8-K as Exhibit 99.1. The Company from time to time presents and/or distributes the presentation to the investment community during conferences and meetings to provide updates and summaries of its business. The Company undertakes no obligation to update, supplement, or amend the materials attached hereto as Exhibit 99.1.

Prompts

Inhibrx Biosciences, Inc. (ticker INBX), listed in United States.

Company History

Date Change Detail
Jan 29, 2024 Renamed INHIBRX, INC. → INHIBRX BIOSCIENCES, INC.
— Re-registered Now files as Inhibrx Biosciences, Inc. (CIK 2007919), succeeding Inhibrx, Inc. (CIK 1739614). Filings under both are this company's.

ETFs Holding Inhibrx Biosciences, Inc.

ETF Weight in ETF Shares Market value As of
CANC 0.43% 7,084 $ 897.543K Aug 31, 2026
VFMO 0.16% 24,867 $ 3.151M Aug 31, 2026
RESM 0.03% 13 $ 1,231.75 Jun 30, 2026
MSSM 0.01% 674 $ 85.396K Aug 31, 2026
FESM 0.00% 10 $ 947.50 Jun 30, 2026
AVUQ 0.00% 36 $ 2,795.76 Nov 16, 2026